RUA Bioscience (NZX:RUA)
NZX announcement history & article coverage
Transparent by design.
Announcments by RUA Bioscience (NZX:RUA) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Ongoing Disclosure Notice - Teresa Ciprian
Ongoing Disclosure Notice - Panapa Ehau
Ongoing Disclosure Notice - Antony Barclay
Ongoing Disclosure Notice - Anna Stove
Capital Change Notice
Results of the 2026 Annual Shareholders' Meeting
ASM Presentation FY26
ASM Letter FY26
CEO's Commentary ASM FY26
Chair's Commentary ASM FY26
Results of Capital Raise
Rua Bioscience raises NZ$1.0 million in undersubscribed Rights Offer
Rua partners with Curaleaf Laboratories for UK distribution
Rua partners to supply medicinal MDMA in New Zealand
Opening of Rights Offer
Capital Change Notice
Quotation Notice - Rua Bioscience Limited (“RUARC") Rights
Coporate Action Notice
Rua Bioscience announces NZD 2.83 million renounceable rights issue
Rua Bioscience Offer Announcement
Rua launches NZ$2.8m rights offer to fund growth after securing expected NZ$10m UK agreement
Rua Bioscience Offer Document
Rua launches NZ$2.83m rights offer to fund growth and working capital
Rua Bioscience Offer Presentation
Rua seeks up to NZ$2.8m to fund medicinal cannabis growth and UK supply agreement
Rua Bisocience Cleansing Statement
Rua Bioscience launches up to NZ$2.83m 1-for-3 rights offer
Rua Bioscience Proxy Voting Form
Rua Bioscience Notice of Meeting 2026
Rua Bioscience FY26 Annual Report
Rua Bioscience lifts FY26 revenue 71% but auditor flags material going-concern uncertainty
Rua Bioscience FY26 Annual Report Announcement
Rua Bioscience reports 53% revenue growth and signs UK agreement worth NZ$10 million
Capital Change Notice - Convertible Note
Commencement of direct distribution from Tairawhiti
FY26 Preliminary Financial Results
Rua Bioscience reports increased revenue but sustained losses with going concern risks
FY26 Preliminary Financial Results Summary
Rua Bioscience reports 54% revenue growth and stable net loss for FY26, no dividend declared
FY26 Preliminary Financial Results Announcement
Rua Bioscience reports 71% revenue growth and secures major UK export deal in FY26
Capital Change Notice
Capital Change Notice - Convertible Note
Annual Shareholders’ Meeting and Director Nominations
Rua Bioscience approves Convertible Note Facility
Rua Bioscience approves NZ$600k convertible note facility to boost UK sales growth
Capital Change Notice